Anyone care to muse about appropriate investment strategies based on the not previously feasible research approaches that might now be possible?

Should we expect to see faster progress in large well capitalized bioscience companies -- or a sudden increase in the viability of smaller biotech and/or biotech startups ...? Are we gonna see top talent fleeing the old biotech companies to start their own ventures with a new belief that the potential for huge reward might suddenly seem achievable?

What kind of companies do we think will be the first that are able to translate this new knowledge into profits?